Issues related to prescription drug pricing, vaccines, animal health, and maternal health; Issues related to Section 340B of the Public Health Service Act.
Issues related to prescription drug pricing, vaccines, animal health, and maternal health.
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Duration: July 1, 2013
to
December 31, 2021
General Issues: Health Issues , Medicare/Medicaid , Pharmacy , Consumer Issues/Safety/Protection , Budget/Appropriations , Trade (Domestic & Foreign) , Taxation/Internal Revenue Code
Spending: about $720,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Jeff Forbes
Staff Director, Senate Finance Committee
Chief of Staff, Senator Max Baucus
Deputy Asst, Special Asst, Deputy Director EOP
Libby Greer
Chief of Staff, Rep. Allen Boyd
Francesca McCrary
Legislative Assistant, Elijah Cummings (2016-2017); Professional Staff, House Oversight Reform Committee (2016-2016)
Cindy Brown
Leg Assistant, Rep. Stupak, 1993-1994; Leg Director, Rep. Kind, 1999-
2002; Chief of Staff, Rep. Kind, 2003-2009
Zachary Williams
n/a
Ryan Welch
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2021
Forbes-Tate terminated an engagement in which they represented Merck on Jan. 16, 2022.
Original Filing: 301323455.xml
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health; Issues related to Section 340B of the Public Health Service Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2021
In Q3, Forbes-Tate lobbied for Merck , earning $50,000. The report was filed on Oct. 18, 2021.
Original Filing: 301301782.xml
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health; Issues related to Section 340B of the Public Health Service Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2021
In Q2, Forbes-Tate lobbied for Merck , earning $50,000. The report was filed on July 16, 2021.
Original Filing: 301278287.xml
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health; Issues related to Section 340B of the Public Health Service Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, Forbes-Tate lobbied for Merck , earning $50,000. The report was filed on April 17, 2021.
Original Filing: 301255092.xml
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health; Issues related to Section 340B of the Public Health Service Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
Lobbying Issues
Issues regarding implementation of the Consolidated Appropriations Act, 2021 (Public Law No: 116-260); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2020
In Q4, Forbes-Tate lobbied for Merck , earning $50,000. The report was filed on Jan. 19, 2021.
Original Filing: 301236232.xml
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health; Issues related to DISARM Act (S. 1712/H.R. 4100); Issues related to Section 340B of the Public Health Service Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
Lobbying Issues
Issues related to H.R. 925 - The Heroes Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2020
In Q3, Forbes-Tate lobbied for Merck , earning $50,000. The report was filed on Oct. 18, 2020.
Original Filing: 301212867.xml
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health; Issues related to DISARM Act (S. 1712/H.R. 4100); Issues related to Section 340B of the Public Health Service Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
Lobbying Issues
Issues related to H.R. 925 - The Heroes Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2020
In Q2, Forbes-Tate lobbied for Merck , earning $50,000. The report was filed on July 18, 2020.
Original Filing: 301192929.xml
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health; Issues related to DISARM Act (S. 1712/H.R. 4100).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
1st Quarter, 2020
In Q1, Forbes-Tate lobbied for Merck , earning $50,000. The report was filed on April 19, 2020.
Original Filing: 301172505.xml
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Health Issues Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
4th Quarter, 2019
In Q4, Forbes-Tate lobbied for Merck , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301124638.xml
Lobbying Issues
Issues related to prescription drug pricing, vaccines, animal health, and maternal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, vaccines, and animal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
3rd Quarter, 2019
In Q3, Forbes-Tate lobbied for Merck , earning $50,000. The report was filed on Oct. 20, 2019.
Original Filing: 301072368.xml
Lobbying Issues
Issues related to Rx drug pricing; Issues related to 340b; Issues related to vaccines; Issues related to animal health; Issues related to maternal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to Rx drug pricing; Issues related to 340b; Issues related to vaccines; Issues related to animal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
2nd Quarter, 2019
In Q2, Forbes-Tate lobbied for Merck , earning $50,000. The report was filed on July 21, 2019.
Original Filing: 301053812.xml
Lobbying Issues
Issues related to Rx drug pricing; Issues related to 340b; Issues related to vaccines; Issues related to animal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Health Issues Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
1st Quarter, 2019
In Q1, Forbes-Tate lobbied for Merck , earning $50,000. The report was filed on April 22, 2019.
Original Filing: 301034801.xml
Lobbying Issues
Issues related to Rx Drug Pricing; Issues related to 340b; Issues related to vaccines; Issues related to animal health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Health Issues Medicare/Medicaid Pharmacy Consumer Issues/Safety/Protection
1st Quarter, 2019
Forbes-Tate filed a lobbying registration on March 19, 2019 to represent Merck, effective Jan. 16, 2019.
Original Filing: 301021688.xml
Issue(s) they said they’d lobby about: Issues related to Rx Drug Pricing; Issues related to 340b; Issues related to vaccines; Issues related to animal health. .
1st Quarter, 2014
Forbes-Tate terminated an engagement in which they represented Merck on April 18, 2014.
Original Filing: 300640733.xml
Lobbying Issues
Issues related to Part D Medicare, the drug industry, and foreign aid maternal and child health; issues related to low income subsidy for Medicare
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to vaccines, PCORI, ASP+6 and 340B; issues related to the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to pharmaceutical drug safety track and trace program legislation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to comparative effectiveness, issues related to the Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations; PNTR with Russia.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit and corporate tax reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2013
In Q4, Forbes-Tate lobbied for Merck , earning $40,000. The report was filed on Jan. 21, 2014.
Original Filing: 300623829.xml
Lobbying Issues
Issues related to Part D Medicare, the drug industry, and foreign aid maternal and child health; issues related to low income subsidy for Medicare
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to vaccines, PCORI, ASP+6 and 340B; issues related to the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to pharmaceutical drug safety track and trace program legislation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to comparative effectiveness, issues related to the Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations; PNTR with Russia.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit and corporate tax reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2013
In Q3, Forbes-Tate lobbied for Merck , earning $40,000. The report was filed on Jan. 6, 2014.
Original Filing: 300611544.xml
Lobbying Issues
Issues related to Part D Medicare, the drug industry, and foreign aid maternal and child health.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to vaccines, PCORI, ASP+6 and 340B; issues related to the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to pharmaceutical drug safety track and trace program legislation.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to comparative effectiveness, issues related to the Independent Payment Advisory Board.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues relating to trade negotiations; PNTR with Russia.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit and corporate tax reform.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2013
Forbes-Tate filed a lobbying registration on Oct. 3, 2013 to represent Merck, effective July 1, 2013.
Original Filing: 300590851.xml
Issue(s) they said they’d lobby about: Issues related to Part D Medicare, the drug industry, vaccines, PCORI, ASP+6 and 340B; issues related to the Prescription Drug User Fee Act; issues related to pharmaceutical drug safety track and trace program legislation; issues related to comparative effectiveness, issues related to the Independent Payment Advisory Board; Issues relating to trade negotiations; PNTR with Russia; Issues related to international tax, check the box, and tax deferral; issues related to the R&D tax credit and corporate tax reform. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate